Silence Therapeutics (SLN) Total Non-Current Liabilities (2019 - 2023)

Silence Therapeutics (SLN) has 5 years of Total Non-Current Liabilities data on file, last reported at $73.2 million in Q4 2023.

• For the quarter ending Q4 2023, Total Non-Current Liabilities fell 1.65% year-over-year to $73.2 million; the trailing twelve-month figure through Dec 2023 stood at $73.2 million (down 1.65% YoY), and the FY2023 full-year result was $73.2 million, down 6.79% from the prior year.
• Total Non-Current Liabilities slipped to $73.2 million in Q4 2023, from $74.5 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $97.7 million in Q4 2021 to a low of $19.9 million in Q4 2019.
• A 5-year average of $66.6 million and a median of $73.2 million in 2023 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities jumped 239.82% in 2020 and retreated 23.81% in 2022, its largest moves.
• Tracing SLN's Total Non-Current Liabilities over 5 years: stood at $19.9 million in 2019, then jumped by 239.82% to $67.8 million in 2020, then soared by 44.17% to $97.7 million in 2021, then decreased by 23.81% to $74.5 million in 2022, then decreased by 1.65% to $73.2 million in 2023.
• Business Quant data shows SLN's Total Non-Current Liabilities at $73.2 million in Q4 2023, $74.5 million in Q4 2022, and $97.7 million in Q4 2021.